Anthony John Iafrate, M.D.,Ph.D.
Co-Author
This page shows the publications co-authored by Anthony Iafrate and Alejandro Balazs.
Connection Strength
2.434
-
Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines. J Infect Dis. 2022 Apr 01; 225(7):1141-1150.
Score: 0.249
-
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022 02 03; 185(3):457-466.e4.
Score: 0.245
-
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. medRxiv. 2021 Dec 14.
Score: 0.244
-
Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines. medRxiv. 2021 Oct 13.
Score: 0.241
-
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021 Apr 29; 184(9):2523.
Score: 0.233
-
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv. 2021 Mar 12.
Score: 0.231
-
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021 04 29; 184(9):2372-2383.e9.
Score: 0.231
-
COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021 01 21; 184(2):476-488.e11.
Score: 0.228
-
COVID-19 neutralizing antibodies predict disease severity and survival. medRxiv. 2020 Oct 20.
Score: 0.225
-
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell. 2022 Mar 31; 185(7):1259.
Score: 0.062
-
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell. 2022 03 17; 185(6):1041-1051.e6.
Score: 0.062
-
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals. medRxiv. 2022 Jan 05.
Score: 0.061
-
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer Cell. 2022 01 10; 40(1):103-108.e2.
Score: 0.061
-
Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. J Clin Oncol. 2022 01 01; 40(1):12-23.
Score: 0.061
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.